Medibimb Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-01-2025
- Paid Up Capital ₹ 3.73 M
as on 03-01-2025
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -90.00%
(FY 2023)
- Profit -401.66%
(FY 2023)
- Ebitda -155.84%
(FY 2023)
- Net Worth -465.64%
(FY 2023)
- Total Assets -36.67%
(FY 2023)
About Medibimb Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.73 M, as per Ministry of Corporate Affairs (MCA) records.
Lakshmoji Tejomurtula, Muthukumar Rajamani, and Ramoji Tejomurtula serve as directors at the Company.
- CIN/LLPIN
U74999KA2018PTC117110
- Company No.
117110
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Medibimb Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muthukumar Rajamani  | Additional Director | 01-Oct-2018 | Current |
| Lakshmoji Tejomurtula | Director | 30-Sep-2018 | Current |
| Ramoji Tejomurtula | Director | 30-Sep-2018 | Current |
Financial Performance of Medibimb Lifesciences.
Medibimb Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 90% decrease. The company also saw a substantial fall in profitability, with a 401.66% decrease in profit. The company's net worth observed a substantial decline by a decrease of 465.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medibimb Lifesciences?
In 2023, Medibimb Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Therabimb Lifesciences Private LimitedActive 11 years 3 monthsLakshmoji Tejomurtula is a mutual person
- Sathabhishou Healthcare Initiatives Private LimitedActive 6 years 5 months
Lakshmoji Tejomurtula and Ramoji Tejomurtula are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medibimb Lifesciences?
Unlock and access historical data on people associated with Medibimb Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medibimb Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medibimb Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_377839.webp){kind=small}
